Floatz logo

TAMOXIFEN

High Risk

National Cancer Institute (NCI)Small moleculePhase 3Dormant
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
81/ 100

Competitive context

11 Active assets in the High Risk cohort.

Asset / SponsorPhaseRating
FILGRASTIM
The First Affiliated Hospital of Soochow University
Phase 4BB
DEXAMETHASONE
The First Affiliated Hospital of Soochow University
Phase 4BB
Bortezomib
The First Affiliated Hospital of Soochow University
Phase 4BB
cc-5013
The First Affiliated Hospital of Soochow University
Phase 4BB
CIS-DIAMMINEDICHLOROPLATINUM II
The First Affiliated Hospital of Soochow University
Phase 4B

View all 17 →

Same molecule, other indications

TAMOXIFEN is also rated in:

estrogen-receptor positive breast cancerDormant
BBB
Indicative ·
77 / 100
View asset →
breast carcinomaDormant
BBB
Indicative ·
75 / 100
View asset →
invasive breast carcinomaDormant
BBB
Indicative ·
75 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →